ArticleSchizophrenia bulletin2006
Treatment of schizophrenia negative symptoms: future prospects.
Article in Schizophrenia bulletin, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Trauma-focused psychological interventions for psychosis: Meta-analytic evidence of differential effects on delusions and hallucinations.Psychological medicine · 2026Pooled it
- Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials.Schizophrenia bulletin · 2015Pooled it
- Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.Psychiatry research · 2014Pooled it
- Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial.The international journal of neuropsychopharmacology · 2020Trial
- Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial.Psychotherapy and psychosomatics · 2019Trial
- Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.Schizophrenia bulletin · 2016Trial
- Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age.Molecular psychiatry · 2015Trial
- Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy.Psychiatry research · 2013Trial
- A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013Trial
- Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial.Psychopharmacology · 2011Trial
- HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.Psychopharmacology · 2009Trial
- Subtyping first-episode psychosis based on longitudinal symptom trajectories using machine learning.Npj mental health research · 2025Article
- Somatic symptoms in schizophrenia: Association with socio-demographic and clinical characteristics, disability and quality of life.Indian journal of psychiatry · 2023Article
- Facial and Vocal Markers of Schizophrenia Measured Using Remote Smartphone Assessments: Observational Study.JMIR formative research · 2022Article
- Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.Therapeutic advances in psychopharmacology · 2022Article
- Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review.Neurology international · 2021Review
- Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).Frontiers in psychiatry · 2021Article
- Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy.Pharmacology, biochemistry, and behavior · 2019Article
- Impact of Positive Emotion Regulation Training on Negative Symptoms and Social Functioning in Schizophrenia: A Field Test.Frontiers in psychiatry · 2019Article
- Repetitive transcranial magnetic stimulation as an adjunctive treatment for negative symptoms and cognitive impairment in patients with schizophrenia: a randomized, double-blind, sham-controlled trial.Neuropsychiatric disease and treatment · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New findings from neuroscience, genetics, and experimental psychology have emerged that provide alternative explanations of many negative symptoms. We review the continuing limitations in treatment and discuss possible sources of heterogeneity among negative symptoms. We also anticipate conceptual uncertainties that may arise with forthcoming treatment developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.